AGIO booked one of its biggest single-day gains in recent months on April 29, while short sellers have been adding quietly in the background — a divergence that sets up an interesting read into next week's earnings.
The stock jumped 13.1% on Wednesday to close at $28.05, extending a weekly gain of roughly 5%. That pop came on the same day the company appears to have made a clinical announcement, given the earnings event log flags an April 29 disclosure. The one-month picture remains in the red, down about 4.7% — so Wednesday's move partially reverses a softer patch, not an extension of a clean uptrend.
The short side is the more layered story. Short interest has climbed 9.4% over the past month and 3.8% this week alone, landing at approximately 11.8% of the free float — a meaningful short position for a biotech of this size. That build happened despite the price spike: shorts added around mid-April, pushed higher through last week, and have barely retreated even as the stock rallied hard. One plausible read is that the position reflects the upcoming May 7 earnings event rather than a directional view on Pyrukynd alone. The borrow market, by contrast, is loose. The cost to borrow is just 0.55% annually — almost nothing — and availability is high, meaning there is ample room to add short exposure without a squeeze dynamic in view. The ORTEX short score of 56 sits in moderate territory and has actually drifted lower from a recent peak near 58.8 in mid-April, suggesting the short conviction, while present, isn't intensifying rapidly.
Options traders are leaning the other way. The put/call ratio is running at 0.185 — modestly above its 20-day average of 0.169 but far from stressed, with a z-score just below 1.75. For context, the 52-week high on PCR for AGIO has been 1.44, so current options positioning is nowhere near defensively loaded. That's a meaningful contrast with the short interest build: shorts are adding, but the options market is still skewed heavily toward calls. The result is a positioning split — elevated directional shorts facing an options complex that remains bullishly tilted.
The analyst community has been trimming targets in recent weeks without abandoning Buy ratings. Truist cut its target today from $39 to $36 while maintaining Buy, and Bank of America moved similarly last week — down from $44 to $41, Buy maintained. Both Goldman Sachs and JPMorgan, which hold Neutral ratings, raised their targets in early April, taking them to $32 and $36 respectively — effectively validating a floor while declining to chase the upside. The mean price target sits near $41, roughly 46% above today's close. That gap is significant but should be read carefully: the stock is a pre-profitability biotech burning around $303 million in operating cash annually on roughly $100 million in revenue, with a net loss expected near $378 million for the year. The bear case centres on Phase 3 setbacks in sickle cell disease and competitive pressure from Novo Nordisk and Fulcrum in the PK activator space. Bulls point to Pyrukynd's rare disease positioning and a net cash position that limits near-term financing risk.
On the institutional side, State Street reported a significant addition of 845,000 shares as of March 31 and BlackRock added nearly 690,000 — both moves of scale. Armistice Capital, a hedge fund, held 3 million shares at year-end after adding 2.27 million in the prior quarter, a position worth watching for changes in Q1 filings. Insiders were mostly recipients of equity awards in early April, with the CEO and CFO executing modest tax-related sales around the same period — routine rather than directional.
The next scheduled earnings release is May 7. The one prior print with available reaction data — February 12 — generated just a 0.9% next-day move and a 3.1% five-day drift, suggesting the stock does not historically gap dramatically on numbers alone. What will matter next week is any additional clinical readout or commentary on the sickle cell program, given that the pipeline read-through is what drove much of the recent short interest build.
See the live data behind this article on ORTEX.
Open AGIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
